Background and purpose: Pulmonary arterial hypertension (PAH) is an incurable, incapacitating disorder resulting from increased pulmonary vascular resistance, pulmonary arterial remodeling and right ventricular failure. In pre-clinical models, combination of a phosphodiesterase 5 inhibitor (PDE5i) with a neprilysin inhibitor augments natriuretic peptide bioactivity, promotes cyclic GMP signaling, and reverses the structural and hemodynamic deficits that characterize PAH. Herein, we conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of repurposing the neprilysin inhibitor, racecadotril, in PAH.
and contemporary strategies to improve therapy have focused on developing drug combinations that synergize in the pulmonary circulation, improving hemodynamics and reversing structural remodeling (Ghofrani et al., 2002; Hoeper, Faulenbach, Golpon, Winkler, Welte & Niedermeyer, 2004; Humbert et al., 2004) .
Targeting cyclic GMP (cGMP) is effective in treating PH, exemplified by the clinical use of phosphodiesterase 5 inhibitors (PDE5i) (Galie et al., 2005) and soluble guanylyl cyclase (NO-sensitive GC-1 & GC-2; 'sGC') stimulators (Ghofrani et al., 2013) . However, these approaches only slow disease progression rather than offering resolution. Pre-clinical studies exploring cGMP signaling in the pulmonary circulation have provided compelling evidence to support atrial natriuretic peptide (ANP) and/or brain natriuretic peptide (BNP) -driven cGMP production in optimizing cGMP-based therapy founded on PDE inhibition, both in terms of efficacy and (pulmonary) selectivity. For example, the beneficial effects of PDE5i in experimental models of chronic hypoxia-induced PH are blunted in animals lacking GC-A (the cognate receptor for ANP and BNP) (Zhao, Mason, Strange, Walker & Wilkins, 2003) ; a similarly exacerbated phenotype in observed in GC-A -/-animals with bleomycintriggered pulmonary fibrosis and secondary PH, with an associated loss of efficacy of PDE5i (Baliga, Scotton, Trinder, Chambers, MacAllister & Hobbs, 2014) . Furthermore, infusion of natriuretic peptides in the presence of the PDE5i sildenafil, synergistically reduces pulmonary artery pressure in hypoxia-induced PH (Preston, Hill, Gambardella, Warburton & Klinger, 2004 ); a similar interaction has been reported between urodilatin (a renal-specific ANP variant) and the PDE5i dipyridamole (Schermuly et al., 2001) . Similarly, infusion of monoclonal antibodies neutralizing ANP stimulates the development of PH in response to hypoxia (Raffestin et al., 1992) , while exogenously administered or adenovirus-mediated natriuretic peptide supplementation protects against PH and the accompanying RVH (Jin, Yang, Chen, Jackson & Oparil, 1988; Klinger et al., 1993; Louzier et al., 2001) . Such findings suggest that the mechanism of pulmonary selectivity of PDE5i depends on the bioactivity of natriuretic peptides and, additionally, that in PH release of natriuretic peptides represents a cytoprotective mechanism that slows disease progression.
One potential mechanism that might be utilized pharmacologically in PH to promote this protective role of natriuretic peptides is to inhibit the enzyme neprilysin (or neutral endopeptidase, NEP). NEP is a membrane bound zinc metallopeptidase responsible for the metabolism and inactivation of an array of vasodilator (e.g. natriuretic peptides, adrenomedullin, vasoactive intestinal peptide) and
vasoconstrictor (e.g. Angiotensin II, Endothelin-1 (ET-1)) peptides (Erdos & Skidgel, 1989; Kenny & Stephenson, 1988) . Indeed, pre-clinical evidence indicates that NEP -/mice are less susceptible to hypoxia-induced pulmonary edema (Irwin, Patot, Tucker & Bowen, 2005) and that inhibition of NEP attenuates hypoxia-induced PH by potentiating the action of natriuretic peptides (Klinger, Petit, Warburton, Wrenn, Arnal & Hill, 1993; Thompson, Sheedy & Morice, 1994; Winter, Zhao, Krausz & Hughes, 1991) . These observations fit with the up-regulation of NEP in the pulmonary circulation during acute lung injury and heart failure (Abassi, Kotob, Golomb, Pieruzzi & Keiser, 1995; Hashimoto, Amaya, Oh-Hashi, Kiuchi & Hashimoto, 2010) .
We exploited this 'natriuretic peptide-centric' approach to evaluate the therapeutic potential of a PDE5i and NEPi combination in animal models of PH (Baliga, Scotton, Trinder, Chambers, MacAllister & Hobbs, 2014; Baliga et al., 2008) . Our data showed that this dual therapy is superior to either drug alone in hypoxia-induced PH and PH secondary to pulmonary fibrosis. This held true for both hemodynamic (e.g. pulmonary artery pressure) and structural (e.g. right ventricular hypertrophy, pulmonary arterial remodeling) indices; importantly however, combination therapy did not significantly affect systemic blood pressure, confirming selective targeting of the pulmonary vasculature (Baliga, Scotton, Trinder, Chambers, MacAllister & Hobbs, 2014; Baliga et al., 2008) . Thus, by combining a PDE5i and a NEPi it is possible to harness further the beneficial effects of natriuretic peptide-cGMP signaling, thereby optimizing pulmonary efficacy and selectivity.
A clear advantage of evaluating this novel PDE5i/NEPi combination in PH patients is the availability of existing licensed medications; the PDE5i sildenafil and tadalafil are prescribed for the treatment of PAH and the NEPi, racecadotril, is also licensed for use in secretory diarrhea. In accord, this report describes a randomized, double-blind, placebo controlled trial to assess the safety and efficacy of repurposing racecadotril in PAH patients stable on PDE5i therapy.
METHODS

Study design and participants
This study was a single-center, double-blind, phase IIa, randomized, placebocontrolled trial conducted in two stages (with planned interim and final analyses), to determine whether administration of the NEPi, racecadotril, to patients with pulmonary arterial hypertension (PAH; WHO Group 1) on PDE5i therapy, increases plasma [ANP] and favorably alters pulmonary hemodynamics without affecting mean arterial blood pressure (MABP Step 1
After consenting, patients considered for Step 1 of the trial underwent right heart catheterization (RHC) as routine care. Patients who met the inclusion criteria were randomized to receive a single dose of racecadotril (100mg; p.o.) or matching placebo (concurrently with their existing PDE5i therapy). The access sheath to the catheter was maintained in position so that pulmonary and systemic hemodynamic measurements could be recorded at 1.5 and 2 h following administration of racecadotril or placebo, after which it was removed. Venous blood samples were also collected at baseline, 0, 1, 2, 3 & 6 h following administration of racecadotril or placebo for the assessment of biochemical endpoints.
Step 2
Patients were randomized to receive racecadotril (100mg, tid; p.o.) or matching placebo for 14 days in addition to (and concomitantly with) their current PH-directed therapy. Systemic blood pressure measurements and venous blood samples were taken at baseline (day 0) and day 14. A telephone conversation at day 7 was undertaken to assess the occurrence of any adverse events.
Endpoints
Step 1 The primary endpoint was the maximum change (Δmax) in plasma [ANP] . Step 2 The primary co-endpoints were safety (adverse effects; assessed for seriousness, severity and causality by on-site clinicians and reported to the IDMC) and (Lecomte, 2000) . Racecadotril has a rapid onset of action, with maximal inhibition of NEP at 60 mins following a single dose of 100mg (p.o.) in humans (Lecomte, 2000) ; NEP activity returns to baseline within 8 hours (the biological half-life is approximately 3.5 hours). This PK profile translates to significantly increased plasma ANP levels within 2 h, returning to baseline at approximately 6 h (Kahn et al., 1990) . Racecadotril does not induce or inhibit CYP450 enzymes and the principal route of elimination is renal. Plasma samples were also analyzed for nitrite (NO2 -) and nitrate (NO3 -), as an index of endogenous NO production (total NOx), using chemiluminescence as described previously (Ignarro, Fukuto, Griscavage, Rogers & Byrns, 1993) .
Sample size
Based on previous clinical studies (Berglund, Nyquist, Beermann, Jensen-Urstad & Theodorsson, 1994; Bruins et al., 2004; Tan, Kloppenborg & Benraad, 1989) the between patient standard deviation of the percentage change from baseline in ANP (i.e. primary outcome measure) was estimated as 12.2. Sample size calculations used a two-sided 5% significance level, 80% power and a 2:1 active:placebo randomization ratio.
Step 1 Within each block of 6 patients (in step 1a and step 1b), a sample size of 4 patients on active therapy and 2 patients on placebo enabled detection of a difference between the two groups in the mean % change in ANP of 50%. Combination of the placebo groups from the two blocks of 6 patients, with adjustment for multiple comparisons using the Bonferroni procedure, permitted detection of a difference between placebo and racecadotril in the mean % change in ANP of 21%. By way of precedent, in chronic heart failure 30 mg sinorphan (L-isomer of acetorphan; equivalent to 60 mg of racecadotril) increases plasma ANP by 100% (Kahn et al., 1990) and in cirrhotic patients 100 mg sinorphan elicits a 180% increase in plasma ANP (Dussaule et al., 1991) . In PH patients, a 21% increase was therefore considered conservative.
Using a 2:1 active:placebo ratio, a sample size of 8 patients on active therapy and 4 patients on placebo enabled detect of a difference between the two groups in the mean % change in ANP of 21%. A 2:1 ratio also provide twice as much information on the safety profile of the drug combination, with minimal effect on the difference that would be able to be distinguished.
Early patient safety and biological activity adaptive design
Step 1 of the study was designed with an adaptive early recruitment phase to allow early termination in case of lack of biological activity of racecadotril or harms.
Step 1 was further broken down into two steps:
Step1a
After the first 6 patients received a single dose of 100mg of racecadotril or placebo, the trial stopped recruitment and key clinical parameters and safety data were reviewed in an unblinded fashion by the IDMC who were asked to consider whether a dose of racecadotril has been identified that:
i. on average increases ANP by a minimum of 20% and ii. on average decreases PVR by a minimum of 10% and iii. on average decreases SBP by no more than 10%.
based on whether the 95% confidence interval for the relevant (racecadotril -control) difference excluded any of these pre-specified clinically important changes. The recommendation was to continue recruiting patients without increasing the investigational medicinal product (IMP) dose due to the apparent pharmacodynamic effect.
Step1b
An additional 6 patients were recruited into the study and administered a single dose of 100mg of racecadotril or placebo followed by the IDMC data review in a similar fashion to Step1a. The IDMC recommended proceeding to Step 2 of the trial, recruiting patients at the 100mg dose of racecadotril.
Randomization and blinding
Patients were randomly assigned in a 2:1 ratio to received 100mg of racecadotril or matching placebo using random permuted blocks. The allocation sequence was computer-generated by the trial statistician and concealment of allocation was ensured by the use of an identical inert placebo, with security in place to ensure allocation of unblinded codes could not be accessed by anyone in the trial team other than the statistician and the pharmacist (for manufacturing and labeling purposes).
Statistical analyses
All statistical tests were two-sided with a significance level of 5%. All continuous efficacy outcomes were log transformed for the statistical analyses. Results were back transformed and are presented as geometric means (GM) and 95% confidence intervals (CI), or ratios and 95% CI. All statistical analysis was based on a pre-specified 
Nomenclature of Targets and Ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017) .
RESULTS
Step 1 Overview 17 patients were screened at the Royal Free London NHS Foundation Trust, between February 2014 and December 2015, for entry to Step 1 of the trial. A total of 15 participants were randomized; Of these, two participants did not receive racecadotril (one due to technical difficulties with the RHC and the other was ruled unfit to receive IMP) and one participant was withdrawn & replaced (for logistical reasons). This is depicted in the CONSORT flow chart (Figure 1) . The analysis population for Step1 comprises 9 patients allocated to racecadotril and 4 allocated to placebo.
Characteristics of the study population All baseline and procedural characteristics were similar between groups, except the plasma [CNP] which by chance was higher in the placebo group (Table 1) .
The mean age of the trial participants was 57 years, with 77% (10/13) female. All participants had significantly raised mPAP (45.54±2.8mmHg) and PVR (514.5±39.9dynes/sec/cm -5 ) consistent with a PAH diagnosis.
Primary endpoint
Administration of racecadotril caused an increase in plasma [ANP] that peaked at 2 h and returned to baseline by 6 h (Figure 2) . This pharmacokinetic profile mirrored that observed in previous studies evaluating racecadotril in left heart failure patients and closely aligns with the biological half-life of the drug (Dussaule et al., 1991; Kahn et al., 1990; Lecomte, 2000) . Racecadotril caused a significant increase (79%) in the maximum plasma [ANP] whereas a small decrease was observed in the placebo arm (albeit two patients receiving placebo exhibited an increase in plasma [ANP]; ( Figure   2 ). These data suggest that, akin to previous studies in heart failure, NEP inhibition causes a significant rise in circulating ANP levels.
Secondary endpoints
The increases in plasma [ANP] in patients receiving racecadotril was mirrored temporally and in magnitude by plasma cGMP concentrations ( Figure 2) . Thus, cGMP levels peaked at the 2 h timepoint and were 106% higher compared to baseline, returning to pre-IMP concentrations after 6 h ( Figure 2) . Indeed, plasma [cGMP] was significantly increased in the racecadotril arm per se and in comparison to placebo ( Figure 2) . These data imply that the temporal elevation in circulating ANP concentrations results in a commensurate increase in cGMP formation (via activation of GC-A).
The parallel rise in plasma levels of ANP and cGMP in response to racecadotril exerted a positive influence on pulmonary hemodynamics without having an overt effect on the systemic circulation. In this setting, PVR and PCWP were reduced in patients receiving racecadotril compared to placebo (although one of four patients in the placebo arm also exhibited a reduction in PVR and PCWP), and the peak response on pulmonary hemodynamics (2 h) matched the maximum rise in both plasma [ANP] and [cGMP] (Figure 3) ; indeed, there was a significant correlation between increases in plasma [ANP] and plasma [cGMP] with reductions in PVR (Figure 2) , tendering some elementary indication of causality. A similar trend was observed with mPAP ( Figure 4) in the absence of any overt change in CO or HR (Table 2) . However, there was no significant effect of racecadotril on MABP between the active and control arms ( Figure 4) , with MABP falling modestly over time in both groups.
Importantly, plasma [ET-1] was not changed following exposure to racecadotril ( Figure 5 ). This is a key safety readout since NEP metabolizes a number of vasoactive peptides, including ET-1 (Llorens-Cortes, Huang, Vicart, Gasc, Paulin & Corvol, 1992) , which is known to be a key driver of pathology in PAH and the target of existing therapy (Luscher & Barton, 2000; Stewart, Levy, Cernacek & Langleben, 1991; Williamson et al., 2000) . Additional mechanistic biomarkers were also unaltered following racecadotril administration in comparison to placebo. This included plasma concentrations of other members of the natriuretic peptide family including BNP (Table   2) , NT-proBNP ( Figure 5 ) and CNP ( Table 2) , and plasma NOx (as an index of NO bioactivity) ( Table 2 ). The lack of effect of NEP inhibition on these biomarkers intimates that the rise in plasma [cGMP] and accompanying reductions in PVR and PCWP are solely mediated by increased ANP bioactivity.
Safety
No serious adverse events (SAE) or serious adverse reactions (SAR) were reported in Step 1 of the trial. Only one patient allocated to racecadotril reported (two) minor AEs that were potentially drug-related; vomiting and epistaxis. Full details of the AEs reported by severity grade, seriousness criteria, causality and trial step can be found in Table 5 .
Overview A total of 10 patients were screened at the Royal Free London NHS Foundation Trust, between May 2016 and October 2016, for possible entry to Step 2 of the trial.
Of these, 2 were excluded before they were randomized; one patient was unable to attend further visits, and a second individual declined to participate after initially consenting. Due to logistical difficulties in recruiting patients to this phase of the study only 8 participants were randomized; this fell short of the necessary 12 individuals, randomized 1:2 to the placebo and racecadotril arms, to be powered to detect a 50% difference in plasma [ANP], the primary endpoint. This is depicted in the CONSORT flow chart (Figure 1) . The analysis population for Step 2 comprises 5 patients allocated to racecadotril and 3 allocated to placebo.
Characteristics of the study population & treatment compliance
All baseline and procedural characteristics were similar between groups, except by chance the plasma [ANP], plasma [CNP], plasma [cGMP] and plasma [NOx] were higher in the placebo group (Table 3) . The mean age of the trial participants was 68 years, with 88% (7/8) female.
All patients were treatment compliant; that is, they took at least 30 of the 42 tablets during the repeat dosage schedule of 12-14 days. The median number of capsules taken in the placebo and racecadotril groups was 39 (IQR 39 to 40) and 40
(IQR 37 to 41), respectively.
Primary endpoint
Administration of racecadotril for 14 days caused ~25% increase in plasma
[ANP], whereas those individuals receiving placebo saw a drop in their plasma [ANP] of ~10%; however, an intra-patient analysis did not reveal a significant increase (P=0.19), despite an apparent trend ( Figure 6 ). The clear increase in circulating ANP levels brought about by NEP inhibition in Step 1 was therefore not maintained to the same extent over a period of two weeks in response to t.i.d administration of the same dose of racecadotril.
Secondary endpoints
Despite the inability to detect an increase in plasma [ANP] following chronic dosing, arguably the most important goal of Step 2 was to assess the safety of daily use of racecadotril in patients with PH. Administration of racecadotril over 14 days did not alter MABP, substantiating the acute lack of effect in Step 1 ( Figure 6) ; moreover, chronic administration of racecadotril did not cause any SAEs (see below).
Additional mechanistic biomarkers (e.g. cGMP, BNP, NT-proBNP, CNP & NOx)
were unaltered following racecadotril administration in comparison to placebo (Table   4 ). Again, NEP inhibition did not alter plasma [ET-1] levels (Table 4) , which is critical to any potential therapeutic application of the drug in PAH.
Safety
No serious adverse events (SAE) or serious adverse reactions (SAR) were reported in Step 2 of the trial. Table 5 shows there were a total of 14 minor adverse events (AEs) reported by patients allocated to racecadotril, and thought to be potentially drug-related, included vomiting, epistaxis, dizziness and headache. The difference in the proportion of patients reporting at least one AE between the two arms (i.e. 0.33 in the placebo group vs. 0.80 in the racecadotril) was not statistically significant (p=0.464; Fisher's exact test). Targeting natriuretic peptide signaling may address this aspiration. Evidence from pre-clinical and clinical studies suggests that the therapeutic efficacy of PDE5i in PH is primarily dependent on promoting natriuretic peptide bioactivity rather than NO (Baliga, Scotton, Trinder, Chambers, MacAllister & Hobbs, 2014; Jin, Yang, Chen, Jackson & Oparil, 1988; Klinger et al., 1993; Louzier et al., 2001; Zhao, Mason, Strange, Walker & Wilkins, 2003) . This concept provides a clear rationale for evaluating combination therapy with PDE5i and NEPi (which slow natriuretic peptide inactivation) in PH patients. Indeed, a precedent for such a therapeutic strategy exists in left-sided heart failure; the dual NEPi (sacubitril)-angiotensin receptor blocker Importantly, administration of racecadotril was not associated with an overt increase in circulating ET-1 concentrations. This is an important finding since NEP is thought to underpin a principle route of ET-1 breakdown & inactivation (Llorens-Cortes, Huang, Vicart, Gasc, Paulin & Corvol, 1992) . ET-1 is well-established to contribute to disease progression in PH and pharmacological blockade of its cognate receptor(s), particularly the ETA subtype, is effective in treating the disease (Luscher & Barton, 2000; Stewart, Levy, Cernacek & Langleben, 1991; Williamson et al., 2000) .
DISCUSSION
Thus, at least in this relatively short-term evaluation, the efficacy of NEP inhibition does not appear to be limited by detrimental augmentation of ET-1 bioactivity.
Interestingly, the plasma concentrations of BNP and NT-proBNP did not show a similar significant change in patients receiving racecadotril, which likely reflects the reduced susceptibility of BNP to breakdown by NEP (compared to ANP; (Watanabe, Nakajima, Shimamori & Fujimoto, 1997) . CNP levels were also unaltered in the face of NEP blockade; this is perhaps surprising since this is the preferred natriuretic peptide substrate for NEP (Watanabe, Nakajima, Shimamori & Fujimoto, 1997) . However, CNP acts primarily in a paracrine fashion, and its systemic concentrations might not reflect tissue levels (Potter, 2011) . Finally, and as expected, the circulating NOX concentrations were not altered by NEP inhibition, confirming that the increases in cGMP observed in patients receiving racecadotril were exclusively due to upregulation of ANP/GC-A signaling, and not through activation of NO-driven pathways.
Longer term (14 day) treatment with racecadotril did not appear to give rise to equivalent increases in circulating ANP levels as achieved by acute administration.
This reduced efficacy is likely underpinned by two explanations. First, the study was powered to detect an intra-patient difference in plasma [ANP] of 21%, so since recruitment fell short of the desired total in Step 2 a larger prospective study would be required to corroborate a beneficial effect of this magnitude. Second, the rapid pharmacokinetic and pharmacodynamic profile of racecadotril with respect to plasma
[ANP] demonstrated in Step 1 implies that time of administration is critical to detection of elevated levels. Whilst patients were requested to take their final dose of racecadotril on the morning of their 14 day assessment (concurrently with their PDE5i therapy), the time between consumption and hospital evaluation varied greatly and did not coincide with the peak plasma [ANP] identified in Step 1. However, previous clinical studies in heart failure have demonstrated that NEP inhibition (using ecadotril, omapatrilat or LCZ696) maintains elevated [ANP] and/or [cGMP] chronically, for up to eight months (Campese et al., 2001; Cleland & Swedberg, 1998; McMurray et al., 2014; Packer et al., 2015) , tendering reassurance that NEPi are likely to exert a similar longer-term pharmacological action in the PH patient cohort. Additionally, this trial did not investigate the dose-response relationship for racecadotril in PAH patients, rather the study utilized the licensed dose of this NEPi for safety and repurposing intentions.
Thus, it is possible that the maximum pharmacodynamic effect has not been reached and higher concentrations of racecadotril would exert greater beneficial activity.
Further optimization in this context is warranted. Regardless, it should be noted that the fall in PVR produced by NEP inhibition herein was on top of that provided by existing PDE5i therapy, suggesting current cGMP-centric drugs can be further enhanced.
With respect to safety, racecadotril has a reassuring profile with more than 1 million patient exposures without overt evidence of serious side effects. Whilst there were numerically more adverse events reported by patients taking racecadotril versus placebo, there was not a statistical difference between the two groups; moreover, the adverse events reported by those taking racecadotril were mild and largely expected based on the vascular (vasodilator) and intestinal (diminution of Cl -& water secretion) effects of NEP inhibition, including headache, dizziness & constipation. These observations give reassurance that chronic use of NEPi in the PAH population will be well-tolerated and safe, although a longer-term study will be needed to ratify this.
In sum, this study provides proof-of-concept clinical evidence of the therapeutic potential of repurposing NEP inhibition in PAH. The beneficial effects of NEPi are dependent on endogenous natriuretic peptide bioactivity, synergize with PDE5i, and exhibit a pulmonary-specific action. The dual mechanism of action inherent to a PDE5i/NEPi combination is unique in terms of existing PH therapy (which target one step in the cGMP signaling cascade) and therefore holds a theoretical advantage in treating the disease. These findings warrant a larger-scale, prospective study with this combination therapy in PH patients to determine if efficacy, selectivity and safety are maintained over a longer period with respect to pulmonary hemodynamics, RV function, exercise capacity, and quality of life. 
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